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Abstract More than several hundreds of millions of
people will be diabetic and obese over the next decades in
front of which the actual therapeutic approaches aim at
treating the consequences rather than causes of the
impaired metabolism. This strategy is not efﬁcient and new
paradigms should be found. The wide analysis of the
genome cannot predict or explain more than 10–20% of the
disease, whereas changes in feeding and social behavior
have certainly a major impact. However, the molecular
mechanisms linking environmental factors and genetic
susceptibility were so far not envisioned until the recent
discovery of a hidden source of genomic diversity, i.e., the
metagenome. More than 3 million genes from several
hundreds of species constitute our intestinal microbiome.
First key experiments have demonstrated that this biome
can by itself transfer metabolic disease. The mechanisms
are unknown but could be involved in the modulation of
energy harvesting capacity by the host as well as the low-
grade inﬂammation and the corresponding immune
response on adipose tissue plasticity, hepatic steatosis,
insulin resistance and even the secondary cardiovascular
events. Secreted bacterial factors reach the circulating
blood, and even full bacteria from intestinal microbiota can
reach tissues where inﬂammation is triggered. The last
5 years have demonstrated that intestinal microbiota, at its
molecular level, is a causal factor early in the development
of the diseases. Nonetheless, much more need to be
uncovered in order to identify ﬁrst, new predictive bio-
markers so that preventive strategies based on pre- and
probiotics, and second, new therapeutic strategies against
the cause rather than the consequence of hyperglycemia
and body weight gain.
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Introduction
Metabolic diseases such as diabetes and obesity are
becoming a social problem of utmost importance for all
countries. Their impact on developing countries such as
South Asia is even more dramatic since, besides being
affected by the highest growing rate, the social system can
certainly not afford the corresponding expenses. Therefore,
the disease is poorly treated and pathological complications
are blooming. Indeed, a major outcome linked to the
occurrence of metabolic diseases is the rapid increase in
cardiovascular events leading to death [1]. Over the last
decade, diabetes has been the cause of lethal cardiovascular
events that have progressed the most, since a 62% increase
has been quantiﬁed [2, 3]. Its progression is much higher
than the risk allocated to cholesterol or even hypertension.
Therefore, in Western countries, where metabolic diseases
are installed, as well as in eastern countries, where diabetes
and obesity are strongly emerging, there is a crucial need to
identify ﬁrst risk factors of diabetes and obesity and second
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gies, most likely based on a change in dietary habits or the
use of food complements prebiotic and probiotic, could be
massively launched. Secondly, therapeutic treatments that
aim at treating the cause rather than the consequence of an
increased body weight or glycemia are needed. To this aim,
a new paradigm of metabolic troubles is now emerging,
resulting in the revision of the underlying causal factors.
Diabetes and obesity result from genetic and environ-
mental factors. It can be estimated that point mutations
accounts for less than 10% of the overall metabolic phe-
notype. The low impact of genetics on metabolic diseases
is further reinforced by the growing incidence of diabetes
and obesity over the last decades. The incidence of type 2
diabetes reaches 4–5% in Europe, 8–10% in the USA and
more in South Asia [4]. These numbers have more than
doubled over the last 20 years. Therefore, one can suggest
that even if genetic analyses provide the basis for such
epidemic, changes in our genome cannot be solely
responsible [5]. Numerous other hypotheses have been
proposed. First, epigenetic non-coded factors generate a
new promising era of hypotheses that would need to be
studied and that would not depend on genomic players.
Second, more realistic is the impact of a change in feeding
habits and social behavior that are certainly important
causes of the growing incidence of metabolic diseases.
However, both factors cannot either explain the overall
epidemic. Linked to the environmental hypothesis, recent
evidences have brought up the metagenome hypothesis.
The latter is deﬁned as the overall bacterial genome,
whereas the expression of the corresponding gene repre-
sents the metatranscriptome. This prokaryotic genome,
next to our eukaryotic one, has emerged thanks to recent
advances of high throughput sequencing technologies
allowing to obtain millions reads over a short period of
time and avoiding the need for laboratory cultivation of gut
bacteria [6], even if a recent study seems to reverse this
concept [7]. The recent advances in DNA sequencing
technology have allowed the collection of high-dimen-
sional data from human-associated microbial communities
on an unprecedented scale [8]. In addition, tremendous
efforts have been made in bioinformatic analyses allowing
the encoding and the deciphering of all sequences. Humans
host different metagenomes from multiple locations such
as skin, lungs, vagina, mouth, even if the intestine hosts the
most [9, 10]. In fact, the human gut hosts 100 trillion
microorganisms, encompassing up to thousand of species
at an average concentration of 10
14 per ml and weighing in
average 1.5 kg [11]. The importance of this metagenome
resides in its gene repertoire, 100 times superior than our
eukaryotic nuclear genome [12], providing hence a huge
genetic diversity susceptible to convey a tremendous
amount of functions.
An important concept is that all mammalians were born
sterile, without any ﬂora. Following the ﬁrst hours, days,
and weeks, the mother’s and the environmental ﬂora col-
onized the overall body of the new born in a speciﬁc order
[13]. The initial infant gut microbiota is a simple structure
usually dominated by Biﬁdobacteria, and through a series
of successions and replacements, it shifts to a more com-
plex adult pattern [14–16]. The microbiota also undergoes
substantial changes at the extremes of life, in infants and
older people, the ramiﬁcations of which are still being
explored [17]. However, the adult intestinal microbiota has
been shown to be relatively stable over time [18] and is
sufﬁciently similar between individuals to allow identiﬁ-
cation of a core microbiome comprising 66 dominant
operational taxonomic units (OTUs) that corresponds to
38% of sequence reads from 17 individuals [19]. Eventu-
ally, the core microbiota changes to become distinct in
elderly subjects from that observed for younger adults, with
a greater proportion of Bacteroides spp. and distinct
abundance patterns of Clostridium groups. Ecological rules
govern the shape of microbial diversity throughout the life.
This suggests that each member can interact in a perfect
mutualistic symbiosis with each other and deﬁnes a steady
microbiota [9, 10, 20]. However, before reaching an ideal
microbial ecology the microbes interact with the host. The
interaction of epithelial cells with microbes and compo-
nents released by microbes, including their metabolites, is a
key mediator of the cross-talk between the epithelium and
other cell types [21]. The exchanges between bacteria and
epithelium may differ in the small and large intestine
because of anatomical differences and the extent to which
the secreted mucus layer covers the epithelium. An
important feature is that the mucosa is free of bacteria,
however, this does not rule out that bacterial fragments
might diffuse throughout the mucosa to bind receptors at
the surface of epithelial intestinal cells [22]. These bacte-
rial to host interaction helps to maturate the intestinal
epithelial layer, the mucosal innate immune system, the
enteric nervous system, as well as the intestinal vascular
system [21]. Hence, intestinal microbiota has a strong
impact on the control of numerous major physiological
functions. Whether the ﬁrst years of life can impact adult
physiological functions is suspected. An interesting caveat
is that modern standards of hygiene [23] and/or the switch
from breast feeding to baby bottle may have altered
transmission mechanisms [13, 24]. Similar hypotheses
could be raised regarding premature neonates [25]. Alto-
gether it is conceivable that the early intestinal microbial
colonization at birth may impact the occurrence of meta-
bolic diseases [26]. Recent data suggested that the Biﬁ-
dobacterial count in fecal samples during infancy, as
assessed by FISH with ﬂow cytometry, was higher in
children remaining normal weight over a 7-year follow-up
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infancy in children becoming overweight was associated
with a greater number of Staphylococcus aureus.
Once adult microbiota established, actors such as antibi-
otics, prebiotics, and probiotics could modulateits ecological
architecture. However, although some plasticity does exist,
theseeffectsarealwaysreversible,suggestingthatatighthost-
to-microbiota relationship has been established during the
neonatal life where the host shapes the microbiota and vice
versa[27].Thecorrespondingmechanismscouldbelinkedto
the maturation of the immune system [28] where some bac-
terial species such as the segmented ﬁlamentous bacteria can
largely induce the coordinated maturation of T cells, whose
responses are induced by the whole microbiota. The innate
immune system, as a ﬁrst line of defense, keeps sterile the
intestinalmucosallayerthroughthephagocytosisofinvading
pathogenic bacteria. Secondarily, B lymphocytes will secrete
IgA into the mucosa that will be speciﬁcally directed against
invasive pathogens [29–31]. Eventually, the synthesis by
intestinal epithelial cells of lectin will provide bedding for
commensalmucosalbacteriaandwillregulatethesecretionof
defensin.Thelatters,naturalantibioticssecretedbythePaneth
cells, will select some bacterial genera and species that will
remain close to the intestinal mucosa.
Consideringalltheaboveoptions,itremainstodetermine
the major factors responsible for the epidemic of metabolic
diseases which is rapidly outgrowing. Recently, intestinal
microbiota ecology has been shown to shape metabolic
diseases itself such as obesity [32] and diabetes [33]. High
throughput sequencing analyses have shown a change in
some of the major phyla that will be described in this review
according to the phenotype. However, in humans, a major
question remains as to whether intestinal microbiota is the
consequence or the cause of the observed phenotype.
Although studies using germ-free mice demonstrated the
causal role of intestinal microbiota in triggering metabolic
impairments, it still remains to demonstrate whether the
genetic background may inﬂuence the development of a
speciﬁc microbiota.
That the diet could be a major regulator factor in
shaping gut microbiota and, hence, its relationship with
host metabolism, can be logically assumed, given the
major role of gut microbiota in digestion [34]. In fact, a
comparative study of multiple dietary habits such as her-
bivore, omnivore and carnivore has shown that the
acquirement of a new diet is sufﬁcient to radically modify
gut microbiota, acting as an evolutionary trigger of new
species [35]. In fact, both host diet and phylogeny shape
bacterial variety, which increases from carnivore to her-
bivore to omnivore. In addition, a modern lifestyle shifts
gut microbiota of humans closer to the one of omnivorous
primates [35]. Therefore, it goes without saying that our
intestinal microbiota feeds on the type of food that is
absorbed by changing its ecological structure. Each indi-
vidual bacterium lives in mutualistic ecology with the
others. Therefore, an excess or lack of nutrient may change
the metabolic activity of a given bacterium, which will no
longer or excessively produce such a metabolite essential
or deleterious for the neighboring bacteria. The major
example is oxygen that is been used by the aerobes from
the upper intestinal tract inducing a deep anaerobic state in
the distal intestine allowing hence strict anaerobes to sur-
vive. The use of prebiotics such as non-digestible dietary
polysaccharides as substrates for genera like Biﬁdobacte-
rium will favor their growth and their anti-inﬂammatory
function [36]. Similarly, a fat-enriched diet, which is
widely used to induce metabolic diseases, strongly impacts
the development of diabetes and obesity.
The molecular mechanisms through which a given
intestinal microbiota induces metabolic diseases will be
discussed in this review. Brieﬂy they are linked to an
increased energy harvesting and the triggering of the low-
grade inﬂammatory status characterizing insulin resistance
and obesity [37, 38]. The bacterial molecules responsible
for the triggering of theses physiological functions are
currently been discovered. This will certainly lead to the
identiﬁcation of new therapeutic strategies for the treat-
ment but also for the prevention of metabolic diseases. A
second outcome will be the identiﬁcation of biomarkers
able to predict the development of diabetes and over weight
in absence of any risk factor. This is envisioned since
intestinal microbiota is causal for the development of
metabolic diseases.
Altogether, the new ‘‘microbiota to host paradigm’’ for
the control of metabolic disease is promising. It involves
transversal ﬁelds of investigation such as microbiology,
immunology, metabolism, and bioinformatics. Joining the
different pieces of the puzzle should lead to innovating
preventive and therapeutic strategies that involve pharma-
cological, prebiotic, and probiotic developments as well as
synbiotic approach [39].
Changes in microbiota during metabolic diseases
During the past *160 million years, mammals have
co-evolved with a vast and diverse microbial community
that colonizes our cutaneous and mucosal surfaces. Most of
these microorganisms reside within our gastrointestinal
tract, and their constituency is determined by host phy-
logeny and diet [40, 41]. Since 0.3% of our eukaryotic
genome is modiﬁed over 1 million years, it can be calcu-
lated that 50–55% of our genome has evolved in a tight
relationship with the microbial community generating
strong genetic dependency. Beside this very long-term
genetic evolution, over the last decade, a major observation
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change in intestinal microbiota composition in animals and
humans [32, 42, 43]. The development of high throughput
sequencing technologies, such as pyrosequencing, has
allowed the analysis of feces from obese patients during
body weight loss. Brieﬂy, this technology sequences
millions of 16S rRNA gene fragments per run. The 16S
rRNA is composed of 9 hyper-variable regions (V1–V9)
[44, 45] that represent the target for the ampliﬁcation-based
sequencing. The degree of diversity or homology is pro-
portional to the genetic distance when plotted onto a phy-
logenic tree. Hence, these characteristics allow the
identiﬁcation of bacterial Phyla, Classes, Orders, Families,
Genera and Species when compared with a naı ¨ve data basis
[46]. The longer the sequence the more precise is the
analysis. The use of tags to identify different samples
allows the analysis of several samples at once, reducing
hence the inﬂuence of sequencing differences in the efﬁ-
cacy. However, this strategy reduces as well the depth of
the analysis by limiting the number of reads per sample.
The sequence reads are assigned to the NCBI non-redun-
dant, Clusters of Orthologous Groups (COG) [47], or
Kyoto Encyclopedia of Genes and Genomes (KEGG) [48]
databases. Altogether, on a general basis, the averaging
results from all data sets have been reported as follows:
94% of the tags assigned to the non-redundant database
were bacterial, 3.6% were eukaryotic (0.29% Mus mus-
culus; 0.36% fungal), 1.5% were Archaea (1.4% Euryar-
cheota; 0.07% Crenarcheota), and 0.61% were viral (0.57%
double stranded DNA viruses) [49]. First analyses using
this technique have been performed on obese patients fol-
lowed up during 1 year of restriction calories diets in order
to reduce their body weight. Gordon’s group initially
showed that the obese patients are characterized by chan-
ges in the relative abundance of the two dominant bacterial
divisions, the Bacteroidetes and the Firmicutes [32, 50].
They showed a reduced Bacteriodetes/Firmicutes ratio in
obese patients which evolved toward that of lean patients
during weight loss. Thus, obesity is associated with phy-
lum-level changes in the microbiota and reduced bacterial
diversity [32, 43, 51]. Therefore, a change in intestinal
microbiota was linked to the obese phenotype. Two
hypotheses could be raised based on these results. The
obese phenotype would be secondary to the microbiota or
the contrary. To answer this question, the fecal microbial
communities of adult female monozygotic and dizygotic
twin pairs concordant for leanness or obesity, and their
mothers have been studied [51]. The results reveal that the
human gut microbiome is shared among family members,
but that each person’s gut microbial community varies in
the speciﬁc bacterial lineages present, with a comparable
degree of co-variation between adult monozygotic and
dizygotic twin pairs [51]. These results demonstrate that a
diversity of organismal assemblages can, however, yield a
core microbiome at a gene level and that deviations from
this core are associated with different physiological states,
for example, obese versus lean.
It is noteworthy that this technology evolves rapidly and
that new generations of sequencing with different bioin-
formatic analyses allow an even faster analysis of the
microbiome. These techniques uses the Illumina GAIIx
platform to sequence a diverse array of samples at a depth
averaging of several million reads per sample which is
continuously increasing [52]. The data demonstrate an
excellent consistency in taxonomic recovery and recapture
diversity patterns that were previously reported on the basis
of meta-analysis of many studies from the literature. The
use of this technique has conﬁrmed the existence of the
above-reported core microbiome [51].
Recent data characterized intestinal microbiota in type 2
diabetic patients. The authors described that the propor-
tions of phylum Firmicutes and class Clostridia were sig-
niﬁcantly reduced in the diabetic group compared to the
control group [33]. Furthermore, the ratios of Bacteroidetes
to Firmicutes as well as the ratios of Bacteroides-Prevo-
tella group to C. coccoides-E. rectale group correlated
positively and signiﬁcantly with plasma glucose concen-
tration but not with BMIs. Therefore, bacterial sequences,
speciﬁc for type 2 diabetes rather than obesity, can be
considered as signatures of hyperglycemic syndrome.
Older data reported changes in intestinal microbiota
related to different metabolic phenotypes. Thirty years ago,
it was observed during gastric bypass surgery, a surgical
method now widely performed to treat diabetes and morbid
obesity [53], a change in intestinal microbiota as observed
by culture-based methods [54]. Furthermore, in animal
models of obesity, induced by brain lesion of the ventro-
medial hypothalamus, a change of intestinal microbiota
was also observed suggesting an important impact of the
brain on the control of intestinal microbiota [55]. At that
time, cultivation-based technologies showed changes in
enterocci and lactobacilli.
The use of metagenomic sequences should now help to
precisely deﬁne the role of the brain on the control of
microbiota. Along the same line of observation, the genetic
ablation of the leptin receptor gene in mice harbors a
microbiota that possesses a signiﬁcantly higher percentage
of Firmicutes, and a correspondingly lower percentage of
Bacteroidetes, than their wild-type littermates [49]. This
data set demonstrates that leptin certainly regulates gut
microbiota. The molecular relays linking leptin to the
microbiome are unknown but the data suggest that its
action would be through either its central effect or via the
induction of obesity. Furthermore, it has been recently
shown a relationship between gut microbiota and brain
development since germ-free mice displayed increased
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with speciﬁc pathogen-free (SPF) mice with a normal gut
microbiota [56]. In particular, the authors showed that the
microbial colonization initiates signaling mechanisms
capable to affect neuronal circuits involved in motor con-
trol and anxiety control.
Another hypothesis would be linked to the role played by
hormones on the immune system which by itself can shape
intestinal microbiota as shown for type 1 diabetes models,
where the immune system is impaired and in other instances
as well [57–59]. Indeed, one potential outcome of the adap-
tivecoevolutionofhumansandbacteriaisthedevelopmentof
commensal relationship [60]. An important mechanism
involves the secretion of antimicrobial molecules belonging
to the defensin familyor membersof the RNAse family such
as angiogenin [58, 59]. These molecules, produced by
intestinal Paneth cells, are secreted into the gut lumen and
have bactericidal activity against intestinal microbes. Their
expression is induced by Bacteroides thetaiotaomicron,a
predominant member of the gut microﬂora. Mice deleted
from the corresponding genes have different microbiota,
revealing a mechanism whereby intestinal commensal bac-
teria inﬂuence gut microbial ecology and shape innate
immunity [58]. The immune system can then regulate the
secretion of defensin and shapes the microbial community
[61].Therefore,onemightsuggestthatinmetabolicdiseases,
the important role played by inﬂammation [37, 38, 62],
mostly due to an impaired immune system, could differently
shape intestinal microbiota.
Diet and nutritional status are amongst the most
important modiﬁable determinants of human health. Fur-
thermore, a change in feeding habits is most likely the most
prevalent factor susceptible to induce metabolic diseases.
Many studies have reported direct links between diet and
the structure of the gut microbiome in mouse models. One
recent example observed that microbiome structure rapidly
shifts in response to a change from a low-fat, plant-based
diet to a high-sugar, high-fat diet, modifying both the
available metabolic pathways and actual gene expression
[63, 64]. Furthermore, the change in feeding habits was
associated with an increased intestinal permeability to LPS
leading to a state of insulin resistance [3, 65]. This latter
study further demonstrated that the change in intestinal
microbiota was also associated with a different suscepti-
bility to antibiotic treatment [65]. The high-fat diet-fed
mice were more sensitive to the antibiotic treatment sug-
gesting that the new microbial ecology that follows the
dietary treatment was very fragile. Over the last decades,
the proportion of fat in diet has mostly replaced that of
dietary ﬁbers, reducing hence the prebiotic effect of the
latters. Therefore, intestinal microbiota has, at least in
part, changed in response to the new feeding habit. Hence,
new antigenic determinants and risk factors for the
immunomodulation and the occurrence of diabetes could
be related to the change in microbiome. This deeply
inﬂuenced the structure of the microbiota within a single
day, changed the representation of metabolic pathways in
the microbiome, and altered microbiome gene expression.
Humanized mice fed the Western diet have increased
adiposity. This trait is transmissible via microbiota trans-
plantation. It is noteworthy that in human studies where
most of the analyses have been made from fecal ﬂora, the
results represent most likely 5–20% of the overall intestinal
microbiota. Therefore, numerous bacterial species are yet
to be described.
The treatment of metabolic disease is challenging.
Bariatric surgery is currently the only available treatment
for morbid obesity that consistently achieves and sustains
substantial weight loss [8, 53]. It is becoming a widely
used procedure even for diabetes and obese patient with
moderate excessive body weight. Various surgical proce-
dures have been developed over the last 50–60 years. The
Roux-en-Y gastric bypass (RYGB) involves creating a
small (about 15–30 mL) gastric pouch from the bottom of
the stomach; then, the distal stomach and proximal small
intestine are bypassed by attaching the distal end of the
mid-jejunum to the proximal gastric pouch (creating the
Roux limb) and then reattaching the biliary and pancreatic
limb at a speciﬁc location along the Roux limb [53, 66].
This very efﬁcient procedure allows the remission from
diabetes and then a major reduction in body weight.
A major consequence is the rapid change in enteroendo-
crine functions, such as the secretion of gut hormones such
as GLP-1, whose origin is yet unknown [67]. However, it is
also associated with a drastic modiﬁcation of microbiota,
which could be the cause of the enteroendocrine change
[68, 69]. Speciﬁcally, the Firmicutes were dominant in
normal-weight and obese individuals but signiﬁcantly
decreased in post-gastric-bypass individuals, who had a
proportional increase in Gammaproteobacteria. Interest-
ingly, numbers of the H2-producing family of Prevotella-
ceae were highly enriched in obese subjects as well as the
Archaea members of the order Methanobacteriales, which
are H2-oxidizing methane producing bacteria. The role is
unknown but could be related to a mechanism important
for increasing energy uptake by the human large intestine
in obese persons. Interestingly, obese and diabetic patients
were also characterized by a reduction in the anti-inﬂam-
matory bacterium F. prausnitzii [68] when compared with
obese patients. Some molecules issued from intestinal
microbiota have been characterized using NMR-based
metabolomic analyses [70]. Gut ﬂora-derived metabolites
such as hippuric acid, trigonelline, 2-hydroxyisobutyrate,
and xanthine contributed most to the classiﬁcation model
and were responsible for the discrimination between
obese and lean individuals. Moreover, the typical obese
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after weight loss induced by bariatric surgery. The causal
role of these molecules could not be demonstrated but it
can at least be suggested that they do represent biomarkers.
Mechanisms through which intestinal microbiota may
lead to the development of hyperglycemia and fat
storage
The storage hypothesis
Intestinal microbes utilize nutrients and produce metabo-
lites that inﬂuence a wide range of human metabolic phe-
notypes, including susceptibility to conditions such as
obesity [3, 42, 49, 71], insulin resistance [3], metabolic
syndrome [89], liver steatosis [72, 73]. Using metagenomic
and biochemical analyses, Gordon’s group demonstrated
that these changes affect the metabolic potential of the gut
microbiota from obese mice [43]. The ‘‘obese microbi-
ome’’ has an increased capacity to harvest energy from the
diet [49]. However, this mechanism was contested by other
studies which suggested that the relationship between the
microbial composition and energy harvesting capacity is
more complex than previously considered [74]. However, a
major point was that this trait is transmissible since colo-
nization of germ-free mice with the microbiota from obese
mice resulted in a signiﬁcantly greater increase in total
body fat (up to 40%) than colonization with the microbiota
from a lean mouse [49, 71]. Consequently, in contrast to
mice with a gut microbiota, germ-free animals are pro-
tected against the obesity that develops after consuming a
Western-style, high-fat, sugar-rich diet [71]. Their persis-
tent lean phenotype is associated with increased skeletal
muscle and liver levels of phosphorylated AMP-activated
protein kinase (AMPK) and its downstream targets
involved in fatty acid oxidation such as the acetylCoA
carboxylase and carnitine-palmitoyltransferase. Further-
more the germ-free mice have increased expression of the
intestinal fasting-induced adipocyte factor (FIAF) that
induces the peroxisomal proliferator-activated receptor
gamma coactivator-1alpha (Pgc-1alpha). Thus, the authors
suggested that germ-free mice were protected from diet-
induced obesity by two independent but complementary
mechanisms that result in increased fatty acid metabolism.
The inﬂammatory hypothesis
Metabolic diseases are characterized by a low-grade
inﬂammation where the role of the innate and adaptive
immune systems is of major importance [37, 38, 62, 75–78].
However, the origin of the factors triggering inﬂammation
beforetheonsetofobesityordiabetesremainsunknown.We
ﬁrst proposed that the lipopolysaccharides (LPS) which are
highly inﬂammatogenic component of the cell wall of the
Gram-negative bacteria were causally involved in the onset
of the low-grade inﬂammation in response to a fat-enriched
diet [3]. Bacterial fragments are recognized by Toll-like
receptors (TLRs) that are a conserved family of integral
membrane pattern-recognition receptors that have a crucial
role in the innate immune system, which is the early host
defense against invading pathogens but are also required for
intestinal homeostasis [79]. Other intracellular receptors,
such as the Nucleotide-binding Oligomerization Domain
(NOD)-like Receptors (NLRs) to bacterial DNA or NOD1
and NOD2, to other fragments such as peptidoglycans, are
involved in innate immunity [80, 81] and could be consid-
ered as target to control inﬂammation. Mice fed a high-fat
diet for a short period of 2 weeks where characterized by a




adipose tissue, liver and muscle inﬂammation developed [3,
82]. The causality of this bacterial factor was demonstrated
since a continuous low-rate infusion of LPS induced most of
the early factors recapitulating metabolic syndrome and
converselymicedeletedfromtheLPSreceptorTLR4,orpart
ofTLR4machinerysuchasCD14,resistedtheoccurrenceof
the disease [83]. Furthermore, adipocytes treated with LPS
developed inﬂammation[84].Numerousdatasuggestedthat
the original site of inﬂammation is indeed the adipose tissue
but recent studies, using conventional and germ-free mice,
suggested that it could be localized into the intestine where
HF Western diet and gut bacteria interact to promote intes-
tinal inﬂammation, which contributes to the progression of
obesity and insulin resistance [85]. The role of intestinal
microbiota was further demonstrated since a chronic anti-
biotic treatment reduced the intensity of the disease in high-
fat diet and ob/ob mice [65, 86]. Plasma LPS concentration
could also be considered as a risk factor since it was present
in excess in the blood of apparently healthy patients feeding
more fat than carbohydrate or proteins [82]. The increased
plasma LPS concentration could be acutely induced by a
single absorption of lipid in human [87] and in mice [3] and
seems to depend on an increased intestinal permeability
through a GLP-2 dependent mechanism [88]. Other evi-
dences showed that the TLR5 receptor was conversely pro-
tecting against metabolic syndrome since mice genetically
deﬁcient in TLR5 exhibited hyperphagia and developed
hallmark features of metabolic syndrome [89]. TLR5 ini-
tially helps defend against infection. It was here shown that
TLR5 controls hyperphagia, hyperlipidemia, hypertension,
insulin resistance, and increased adiposity through the
mechanisms requiring inﬂammation. A further phenotype
wasthatthemetabolicfeaturescorrelatedwithchangesinthe
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wastransmissiblesincethetransplantationofthemicrobiota
from TLR5-deﬁcient to germ-free mice resulted in obesity
and reduced insulin sensitivity. These ﬁndings further
demonstrate that the modulation of the immune system
affects host metabolism by altering gut microbiota.
Taken into account what reported above, a key matter is
to understand how bacterial fragments and LPS reach the
target organs and trigger inﬂammation. LPS molecules are
carried into the blood mostly by lipoproteins where in the
liver they have been proposed to induce hepatitis [90].
Moreover, an antibacterial treatment reduced the diseases
[91]. Therefore, it has been suggested that LPS can be
absorbed by the intestine during the synthesis of chylo-
microns [92, 93] then exchanged with other lipoproteins
[94] that can be chronically transported toward target tis-
sues such as liver [95] or blood vessels [96] and trigger
inﬂammation. However, in an acute situation, a ﬂash
administration of lipoproteins can buffer plasma LPS and
reduce its impact on the acute phase inﬂammation [97, 98].
No hypothesis is so far available for other bacterial
fragments.
Altogether, the huge diversity of intestinal microbiota
allows multiple hypotheses regarding the molecular
mechanisms responsible for metabolic diseases. Certainly,
inﬂammation must be taken into account. One could also
suggest that food intake and energy storage must be
involved in the picture.
Gut microbiota and lipid metabolism
Conclusions from the previous paragraph suggest that
intestinal microbiota, which strongly inﬂuences fat storage
in white adipose tissue, may as well tightly regulate lipid
metabolism and its consequences on cardiovascular dis-
eases. This hypothesis is easily intuitive since the intestine
is the entry door of lipid. Microbiota, although present at
low concentration in the duodenum and jejunum (10
4–
10
5 cell/ml), where most of the lipids are absorbed, would
be informing the intestinal cells with lipid metabolites.
Otherwise an excess of lipids, hence not absorbed, would
be feeding the microbiota present in the large intestine
which would produce informative metabolites as well.
Evidences showed that conventional mice bearing a normal
microbiota were characterized by increased production of
energy metabolites, e.g., pyruvic, citric, fumaric, and malic
acid, when compared with germ-free mice [99]. Con-
versely, plasma levels of cholesterol and a number of lipid
species in the serum triglycerides and phosphatidylcholine
were reduced by the microbiome whereas they were
increased in the tissue such as the adipose tissue and the
liver. This suggested that the clearance of lipids was
increased by the microbiota. The mechanisms remain
unknown but are most likely due to the change in the
bacterial genera and the corresponding microbiome, pres-
ent or not within the ﬂora from the diabetic or obese ani-
mals. Even intestinal cholesterol metabolism is affected by
the intestinal microbiota. In germ-free rats, hepatic
microsomal hydroxylation of steroid hormones and of
lithocholic acid is more efﬁcient than in the conventional
counterparts [100]. A precise example is the discovery of a
Bacteroidetes D8, a cholesterol-reducing bacterium of
human intestinal origin, which was isolated from a senior
male volunteer, with a high capacity to reduce luminal
cholesterol to coprostanol [101]. Several decades ago, the
role of intestinal microbiota on the control of lipid
metabolism was also indirectly suggested since it was
shown that biliary acids can be metabolized by the ﬂora
[102]. In germ-free rats, the amount of urobilin and ster-
cobilin is almost negligible which shows that bilirubin is
reduced to urobilins by the intestinal microbial ﬂora
exclusively. The colonization with different bacterial
strains showed that the metabolism of biliary acids was
differently affected by the type of intestinal microbiota. In
all instances, monocolonization was not sufﬁcient to fully
restore a normal bile acid metabolization.
Surprisingly, the impact of gut microbiota on systemic
metabolism (Fig. 1) has been shown even in relation to
lipid homeostasis in not-metabolically active organs such
as the eye [103]. In a recent study, Oresic et al. compared
the lipid structure of eyes issued from germ-free and con-
ventional mice. The authors analyzed both lens and retina
lipidome by Mass Spectrometry (MS) performed in ion-
negative mode (ESI-), and a total of 140 and 276 lipids
were, respectively, detected. The main ﬁnding was the
microbiota-driven reduction in overall phosphatidylcho-
lines, which suggested an increased exposition to oxidative
stress in conventional mice when compared with germ-free
mice.
However, in the quest of mechanisms linking gut mic-
robiota, lipid metabolism and vascular diseases recent
ﬁnding demonstrate strong molecular hypotheses [104].
Before, discussing these issues, it is noteworthy that car-
diovascular diseases have been linked to infection for
several decades by augmenting pro-atherosclerotic changes
in vascular cells [105]. A microbiome has been found in
atherosclerotic plaques since bacterial DNA can be iden-
tiﬁed in more than 50% of all plaques [106] and its origin
could be intestinal or oral [107]. The vascular risk was
indeed increased in population studies where the plasma
concentration of LPS was increased (Fig. 2)[ 104, 108,
109]. Conversely, anti-LPS molecules such as soluble
CD14 protected against aortic stiffness and hence an
impaired vascular function [110]. Therefore, antibiotic
therapies may have some positive impact on vascular



























Fig. 1 Multiple-sited impact of
gut microbiota on whole host
metabolism. Gut microbes have
been shown or proposed to have
an impact on adipose tissue and
liver fat storage, skeletal muscle




tissue lipid composition in the
retina lens, periodontitis,
behavior and motor activity, and
enteroendocrine metabolism.
The precise bacteria involved
remained to be determined and


















Fig. 2 The inﬂammatory burn: gut microbiota dysbiosis and the
origin of metabolic impairments. The origin of metabolic diseases is
multifactorial but the impact of deleterious feeding habits is certainly
the major factor responsible. This directly modiﬁes intestinal ecology
and we ﬁrst showed that upon an increased intestinal permeability it
led to an increased circulating concentration of LPS from Gram-
negative bacteria of intestinal origin [3, 82] called metabolic
endotoxemia. The inﬂammatory factors LPS and other bacterial
fragments can translocate toward target tissues such as the blood, the
liver, and the adipose depots or the arterial wall to interfere with cells
from the immune system to generate the chronic low-grade inﬂam-
mation required for the development of metabolic and cardiovascular
diseases
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123function [111]. The molecular control of the generation of
atherosclerotic plaques by factors from intestinal original
has been recently shown in a study where the authors used
a metabolomics approach to generate unbiased small-
molecule metabolic proﬁles in plasma that predict risk for
CVD. Three metabolites of the dietary lipid phosphati-
dylcholine—choline, trimethylamine N-oxide (TMAO)
and betaine—were identiﬁed and then shown to predict risk
for CVD in an independent large clinical cohort. Dietary
supplementation and germ-free mouse studies conﬁrmed a
critical role for dietary choline and gut ﬂora in TMAO
production. It was linked to macrophage cholesterol
accumulation and foam cell formation. Hence, the role of
monocytes/macrophages is important in low-grade
inﬂammatory diseases since an increased number favors
coronary collateral growth in type 2 diabetic patients [112].
Eventually the suppression of intestinal microﬂora in ath-
erosclerosis-prone mice inhibited dietary-choline-enhanced
atherosclerosis. Therefore, microbiota from intestinal or
oral origin is now certainly recognized as a risk and a
causal factor of the cascade of events leading to athero-
sclerosis. An interesting hypothesis would be that the
microbiome could control host gene expression via miRNA
[113]. Comparative proﬁling of miRNA expression using
miRNA arrays from conventional and germ-free mice
revealed that mmu-miR-665, which was dysregulated
during colonization, down-regulated Abcc3 expression by
directly targeting the Abcc3 30-UTR [113]. The role of
miRNA on endothelial metabolism has been shown else-
where [114] and therefore one could suggest that intestinal
microbiota could regulate endothelial function and human
atherosclerotic lesions [114]. However, the overall control
of inﬂammation mediated by the innate and adaptive
immune system can certainly regulate the aggressiveness
of the gut ﬂora. Consequently, the truth might rely on a set
of markers associating gut microbiota as a risk factor, the
regulatory role of the immune system and the genetic
background of the individual.
Gut microbiota as a regulator of hepatic steatosis
Hepatic steatosis is one of the major complications of
abdominal obesity, insulin resistance and type 2 diabetes
[115–117]. About 60–80% of these patients developed a
stage of the disease ranging from 1 to 5 where the lowest
limit corresponds to the accumulation of lipid and then to
inﬂammation, apoptosis, ﬁbrosis, liver failure or cancer. It
is now becoming a priority for Europe through the
launching of European programs to fund research. The
argument that intestinal microbiota would be involved in
the triggering of hepatic steatosis originates from obser-
vations that conventionalized animals have 40% more
body fat than germ-free animals [42]. Several molecular
mechanisms have been proposed. An increased intestinal
production of short chain fatty acids would be providing
more energy to the liver [49, 71]. The genetic background
provides a susceptibility to the development of hepatic
steatosis such as in the SV129S6 mouse [72]. In this
instance, the multivariate statistical modeling of the met-
abolomic spectra from urine samples have shown that the
genetic predisposition of the mouse strain to liver steatosis
is associated with disruptions of choline metabolism [72].
It was demonstrated that the symbiotic gut microbiota
converted the choline into methylamines leading to low
circulating levels of plasma phosphatidylcholine and high
urinary excretion of methylamines (dimethylamine, tri-
methylamine, and trimethylamine N-oxide), which redu-
ces the bioavailability of choline and mimics the effect of
choline-deﬁcient diets, causing NAFLD [72, 73]. How-
ever, this model does not involve a key feature which is
that the liver disease is associated with a state of
inﬂammation. The molecular inﬂammatory mechanism
could be attributed to plasma LPS which is increased in
the patients with cirrhosis and in the hepatoportal vein
following alcohol consumption [3, 118, 119]. This
mechanism was dependent on TLR4 and initiates inﬂam-
mation [120]. However, in absence of alcohol consump-
tion, plasma LPS concentration moderately increases in
the blood of mice which develop a fatty liver such as the
high-fat diet-fed mice [3]. This process characterizes a
metabolic endotoxemia and is considered as a triggering
factor of inﬂammation and metabolic diseases. Metabolic
endotoxemia was linked to an increased intestinal per-
meability [65]. The treatment of the mice fed a fat-enri-
ched diet with antibiotics reduced the metabolic
endotoxemia and the accumulation of fat in the liver and
the local inﬂammatory status [65, 86]. In addition, to the
inﬂammatory mechanism, it has been proposed that
intestinal microbiota would be increasing fat accumulation
in the liver through a mechanism involving the regulation
of FIAF [42, 71]. This member of the angiopoietin-like
family of proteins is selectively suppressed in the intes-
tinal epithelium of normal mice by intestinal microbiota.
FIAF is a circulating lipoprotein lipase inhibitor and its
suppression is essential for the microbiota-induced depo-
sition of triglycerides in adipocytes. Indeed, in the obese
diabetic ob/ob mouse, the corresponding microbiome has
an increased capacity to harvest energy from the diet
further fueling the liver with carbon residues generated
through the bacterial fermentation of non-digestible ﬁbers.
Therefore, upon a change of intestinal microbiota, it is
suggested that both increased dietary ﬁber fermentation,
and the induction of metabolic endotoxemia would lead to
accumulate lipids in liver and trigger inﬂammation. This
hypothesis would ﬁt with the rapid development of hepatic
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123steatosis corroborating the change in feeding habits and
hence of intestinal microbiota.
Gut microbiota and type 1 diabetes
Type 1 diabetes is an autoimmune disease which is due to
the speciﬁc destruction of the endocrine insulin secreting
pancreatic beta cells by T lymphocytes [121]. Conse-
quently, a progressive but absolute insulinopenic state
occurs within the following months and years. This
mechanism is irreversible but could be prevented by
immunosuppressive agents when used early enough [122,
123]. The antigens targeted by the immune system have
been partly described and are related to the recognition of
Glutamic Acid Decarboxylase (GAD)-64 proteins. T lym-
phocytes invade the pancreatic islets as described by an
insulitis, and progressively destroy the insulin secreting
cells only [121]. What remains unknown is the process that
prevents from the proper destruction of the autoreacting T
lymphocytes or the system that allows the autoimmune
reaction by misrecognition of the self-antigens such as
GAD64. One could suggest that the maturation of T lym-
phocytes would be impaired. Recent data showed the
critical role of the gastrointestinal microbiota in the pro-
tection or the triggering of type 1 diabetes [57, 124]. The
animal models suitable for such studies are the non-obese
diabetic (NOD) mouse strain, or the BB rat. In both
models, the target pancreatic insulin producing beta cells
are attacked and destroyed by activated immune cells,
leading to type-1 diabetes. The discovery of the role of
intestinal microbiota came from the hygienic hypothesis
[23] following the observation that the incidence of spon-
taneous T1D in the NOD mouse colony can be affected by
the microbial environment in the animal housing facility
[125] or by exposure to microbial stimuli such as injection
with mycobacterium or various microbial products [126,
127]. In human, the incidence of type 1 diabetes has
increased during the past several decades in developed
countries where environmental conditions have dramati-
cally changed [128–131]. This hypothesis suggests that
bacterial antigens would be presented by the innate
immune system to the T lymphocytes very early in life
supporting the notion that immunostimulation can beneﬁt
the maturation of the postnatal immune system [132, 133].
Consequently, in case of misrecognition of the bacterial
antigen, the adaptive immune system will be exacerbating
its aggressiveness against the pancreatic cells and destroy
them. Consequently, the recognition of bacterial determi-
nants from intestinal microbiota would be a triggering
factor of autoimmune disease. The Toll-like receptors
(TLRs) are innate pattern-recognition receptors involved in
host defense that control over commensal bacteria and
maintain tissue integrity [79, 134]. The corresponding
signaling molecule is MyD88 adaptor, therefore mice
lacking this molecular mechanisms were protected against
insulitis [57]. This is dependent on commensal microbes
because germ-free MyD88 knockout mice develop robust
diabetes.
The type of intestinal microbiota is important. That from
NOD mice is most likely inducing diabetes since the col-
onization of these mice with a microbiota from non-type 1
diabetic mice prevented the incidence of diabetes in germ-
free NOD mice. Therefore, both the quality of the intestinal
microbiota and the activation of the innate immune system
control the aggressiveness of T lymphocytes and conse-
quently the development of autoimmune diseases. In the
Biobreeding rat model of type 1 diabetes, it has been found
that the Lactobacillus species present in feces were nega-
tively correlated with type 1 diabetes development [135].
Precisely, two species the L. johnsonii and L. ruteri pre-
vented the effect on type 1 diabetes development [135]. It
was suggested that two strains of bacteria induced changes
in the intestinal mucosal protein and oxidative stress
response leading to low level of IFNc. Consequently,
observations following the administration of antibiotics in
type 1 diabetic Biobreeding rat models showed that the
occurrence of the disease was reduced, which has
strengthened the hypothesis that a speciﬁc intestinal mic-
robiota could induce autoimmunity [136].
Altogether engineering intestinal microbiota by the
mean of prebiotics, probiotics, and food complement, or by
bacterial-derived immunotherapeutic strategies could ben-
eﬁciate the prevention of type 1 diabetes (Fig. 3).
Gut microbiota and periodontitis
Cross-sectionalstudiessuggestastrongassociationbetween
systemic diseases and oral infection, such as periodontal
disease [137–140], which is considered the sixth complica-
tion of diabetes mellitus [141, 142]. Periodontitis is a com-
mon chronic multifactorial infection characterized by an
inﬂammatory reaction against a speciﬁc mouth microbiota.
The latter sets a complex bioﬁlm that is mainly composed of
Gram-negative bacteria in the subgingival microenviron-
ment [143, 144]. Based on this aspect, Saito et al. [145]
hypothesized that the speciﬁc correlation between the per-
iopathogens and the development of obesity might also be
associated with changes in plasma LPS concentration.
Importantly, the endotoxin from the Gram-negative path-
ogenes could be responsible of remote effects of periodontal
disease on systemic health [145]. LPS release in systemic
circulation directly impacts organs such as liver, lung, adi-
pose tissue, skeletal muscle, and heart [146]. The challenge
of this bacterial antigen at multiple organ sites is able to
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123trigger an inﬂammatory reaction, resulting in insulin resis-
tance, ﬁnally leading to metabolic impairments [38]. With
regard to another chronic disease associated with a low-
grade inﬂammation such as atherosclerosis, recent data
demonstrate that bacteria from the oral cavity may correlate
with disease markers of the vascular disease [107]. By tar-
geting the 16S rRNA V1–V2 region by pyrosequencing and
byapplyingqPCRanalysis, dataidentiﬁed sharedsequences
belonging to the Veillonella and Streptococcus groups of
sequences between oral and atherosclerotic plaque samples
within the same individuals. Moreover, in this study, prin-
cipal component analyses suggested that the abundance of
Fusobacterium, one of the ﬁrst colonizers in periodontal
plaque, may directly impact the levels of total cholesterol
and LDL. This evidence shows the translocation of oral
bacterial into systemic circulation. Hence, in light of the
above reported results, many studies have indicated that
treating periodontal disease by reducing oral bacterial
pathogens [147–149] may improve metabolic control in
diabetic patients.
The use of Pre-, Pro-, and Synbiotic to prevent or treat
metabolic troubles
Facing the epidemic of obesity and diabetes, one needs to
recognize that preventive strategies must be used. So far,
appropriate feeding habits are only scarcely applied by
individuals whereas more and more teenagers are under the
inﬂuence of fat- and sugar-enriched diet. Hence, in front of
this social problem new strategies should be envisioned.
One way would be to rehabilitate our intestinal micro-
biota by the mean of pre- or pro-biotics. With regard to
prebiotic there is now much interest in manipulation of the
microbiota composition in order to improve the potentially
beneﬁcial aspects. The prebiotic approach dictates that
non-viable food components are speciﬁcally fermented in
the colon by indigenous bacteria thought to be of positive
value, e.g., biﬁdobacteria, lactobacilli [150, 151]. Any food
ingredient that enters the large intestine is a candidate
prebiotic [152]. Most current attention and success have
been derived using non-digestible oligosaccharides derived
from fructose, xylose, soya, galactose, glucose, and man-
nose with different efﬁcacy on metabolic diseases. The
mechanisms of action remain unclear but could be related
to the regulation of intestinal mucosal biology where the
intestinal mucosa was characterized by higher villi, deeper
crypts, increased number of goblet cells and a thicker
mucus layer on the colonic epithelium [153]. The inhibi-
tion of intestinal permeability to agents such as LPS has
been proposed recently through a mechanism that might be
involving the secretion of enteric peptide such as the glu-
cagon-like peptide 2 [88]. Eventually, intestinal enteroen-
docrine functions could also be targeted by prebiotics
[154]. Fructoligosaccharides increase the production of
glucagon-like peptide 1 that could favor insulin secretion
and activate the gut-brain axis for the control of glucose
metabolism [155].
Other strategy involves the use of bacteria, i.e., probiotic
to restore a healthy intestinal microbiota. Several genera
are currently used and amongst them the most common are
Biﬁdobacteria and Lactobacilli with different beneﬁt for
health. The identiﬁed mechanisms of action are numerous
[156]. They seem to be at least in part related to the
modiﬁcation of the adhesion of certain bacterial strains to







Fig. 3 Therapy strategies
challenging gut microbes. The
discovery of the role of
intestinal microbiota on the
control of metabolic diseases
opens numerous therapeutic
strategies such as prebiotics,
probiotics, and immune
modulation. It also allows the
generation of biomarker
strategies to set predictive
proﬁles, to classify and to
stratify the patients and the
corresponding metabolic and
cardiovascular diseases
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123system through the production of IgA [158] or the induc-
tion of anti-inﬂammatory molecules such as Il10 [159–
161], or the regulation of intestinal permeability [162]. A
recent evidence has clearly demonstrated that a speciﬁc
strain, i.e., the B. longum is able to reduce inﬂammation of
the intestine by producing high amount of acetate from the
fermentation of dietary ﬁbers [163]. Acetate interacts with
the enteric immune system to favor the synthesis of regu-
latory T lymphocytes. Other mechanisms might involve the
production of single-bacterial molecules such as the poly-
saccharide A from Bacteroides fragilis which is required to
suppress pro-inﬂammatory interleukin-17 production by
intestinal immune cells [164]. The metabolic consequences
of the use of probiotics are numerous. Most of them
involve the reduction in body weight [165], non-alcoholic
hepatic steatosis [166–168], or glycemia and insulin
resistance [169, 170].
To the light of the beneﬁcial effects of pre- and pro-
biotics, a new strategy combining both approaches is now
raising and deﬁned as ‘‘synbiotic.’’ Understanding the
mutualistic connection between gut microbiota and host
physiology for the control of metabolism is crucial in the
quest for mechanisms which are responsible of the dramatic
raise of cardiovascular diseases [2, 3]. In this scenario, very
recently a synbiotic strategy has been shown capable of
ameliorating the lipid proﬁle of hypercholesterolemic men
and women. In this study, patients have been given a com-
bination of Lactobacillus acidophilus CHO-220 and inulin
[150, 151] or a placebo, for 12 weeks. Despite the lack of
effect on body weight and energy intake, the synbiotic
treatmentreducedbothtotalandLDLplasmacholesterolvia
a mechanism involving lipid transporters [39]. Therefore,
since triglycerides concentration in lipoproteins is consid-
ered as a main risk factors of atherosclerosis, the authors
suggestedtheatheropreventiveroleofthesynbioticstrategy.
Conclusions: therapeutic and preventing present
and future avenues
We are now facing a new era during which we will have to
understand the role of a new organ rich of more than
3 million genes: gut microbiota. It is doubtless that this
metagenome will be the basis of many new therapeutic
approaches to treat and prevent metabolic diseases and the
corresponding cardiovascular consequences. By under-
standing this new ecology strategies based on prebiotics,
probiotics, even targeted antibiotics could be envisioned.
The identiﬁcation of the eukaryotic genes regulated by gut
microbiota will also be considered as new targets against
which pharmaceutical companies should be able to design
compounds. Eventually, gut microbiota is considered as a
large set of antigens and some of them could serve as the
basis of immunotherapeutical strategies to prevent or to
treat. Diagnostic kits to identify patients at risk or to
classify and stratify the diseases will be helpful for the
clinician to better adapt the therapeutic strategy.
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